Phase II part of EORTC study 26101: The sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma
| Autor: | Paul Clement, Vassilis Golfinopoulos, Emilie Le Rhun, Ahmed Idbaih, Alba A. Brandes, Martin Bendszus, Roger Stupp, Maaike J. Vos, Jean-Sebastien Frenel, Davide Musmeci, Julien Domont, Thierry Gorlia, Wolfgang Wick, Felix Sahm, Michael Platten, Jacoline E C Bromberg, Martin J. van den Bent, François Dubois, Michel Fabbro |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Cancer Research
medicine.medical_specialty Temozolomide Every Two Weeks Bevacizumab Performance status business.industry medicine.medical_treatment Urology Lomustine medicine.disease Surgery Radiation therapy 03 medical and health sciences 0302 clinical medicine Oncology 030220 oncology & carcinogenesis medicine business First Recurrence 030217 neurology & neurosurgery medicine.drug Glioblastoma |
| Zdroj: | Journal of Clinical Oncology. 34:2019-2019 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2016.34.15_suppl.2019 |
| Popis: | 2019Background: Both lomustine (LOM) and bevacizumab (BEV) are approved agents for recurrent or progressive glioblastoma. We aimed at evaluating the optimal treatment sequence (single agent vs sequential vscombination) of these agents in a randomized phase II design. Methods: Progressive patients after initial radiotherapy and temozolomide were randomized 2:2:2:1 between Arm 1: LOM 90 mg/m2 (max. 160 mg) every 6 weeks plus BEV (10 mg/kg) every 2 weeks until progression, subsequent salvage treatment at the investigators best choice (MD choice); Arm 2: LOM 110 mg/m2 (max. 200 mg) every 6 weeks, at progression switch to BEV every two weeks; Arm 3: BEV every 2 weeks, at progression add LOM 90 mg/m2 (max. 160 mg) every 6 weeks and continue BEV; and Arm 4: LOM single agent 110 mg/m2 (max. 200 mg) every 6 weeks, at progression MD choice (arm 4). Eligibility criteria included performance status 0-2, adequate hematological, liver and renal function, and an interval since the end of radiotherapy of ≥ 3 months to ru... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|